These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 2935106)

  • 41. Antihypertensive effect of a new calcium channel blocker, FK 235, in essential hypertension.
    Mizuno K; Hashimoto S; Yabe R; Kunii N; Niimura S; Tani M; Watari H; Fukuchi S
    Res Commun Chem Pathol Pharmacol; 1986 Apr; 52(1):3-15. PubMed ID: 3520729
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Multiple oral doses of nicardipine, a calcium-entry blocker: effects on renal function, plasma renin activity, and aldosterone concentration in mild-to-moderate essential hypertension.
    Baba T; Ishizaki T; Murabayashi S; Aoyagi K; Tamasawa N; Takebe K
    Clin Pharmacol Ther; 1987 Aug; 42(2):232-9. PubMed ID: 3301155
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Muzolimine and nitrendipine in the treatment of arterial hypertension.
    de Divitiis O; Di Somma S; Petitto M; Galderisi M; Iacono C; Fazio S
    Z Kardiol; 1985; 74 Suppl 2():60-5. PubMed ID: 3159163
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Some observations on the effects of a calcium channel blocker, nitrendipine, in early human pregnancy.
    Lawrence MR; Broughton Pipkin F
    Br J Clin Pharmacol; 1987 Jun; 23(6):683-92. PubMed ID: 3300758
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Systemic and regional hemodynamic and humoral effects of nitrendipine in essential hypertension.
    Grossman E; Oren S; Garavaglia GE; Messerli FH; Frohlich ED
    Circulation; 1988 Dec; 78(6):1394-400. PubMed ID: 3191594
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Verapamil and nitrendipine in beta blocker-resistant hypertensive patients].
    Edmonds D; Förster E; Wehling M; Siegenthaler W; Vetter W
    Schweiz Rundsch Med Prax; 1985 May; 74(19):510-3. PubMed ID: 3160098
    [No Abstract]   [Full Text] [Related]  

  • 47. Hemodynamic and metabolic effects of the calcium channel blocking agent nitrendipine.
    Johnson BF; Romero L; Marwaha R
    Clin Pharmacol Ther; 1986 Apr; 39(4):389-94. PubMed ID: 2937598
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Hemodynamic and beta-adrenergic receptor adaptations during long-term beta-adrenoceptor blockade. Studies with acebutolol, atenolol, pindolol, and propranolol in hypertensive patients.
    van den Meiracker AH; Man in't Veld AJ; Boomsma F; Fischberg DJ; Molinoff PB; Schalekamp MA
    Circulation; 1989 Oct; 80(4):903-14. PubMed ID: 2571431
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparison of cardiovascular, renal, and humoral effects of acute administration of two calcium channel blockers in normotensive and hypertensive subjects.
    Leonetti G; Cuspidi C; Sampieri L; Terzoli L; Zanchetti A
    J Cardiovasc Pharmacol; 1982; 4 Suppl 3():S319-24. PubMed ID: 6184561
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Nitrendipine, a new calcium antagonist, in the therapy of arterial hypertension].
    Cosmi F; Mollaioli M; Aimi M; Conti G; Corbacelli C; Bianco C; Ricca M
    Minerva Med; 1985 Nov; 76(42):1983-90. PubMed ID: 2933597
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Hemodynamic, humoral and renal effects of the acute administration of nifedipine in hypertensive patients].
    Cuspidi C; Sampieri L; Leonetti G
    Boll Soc Ital Cardiol; 1979; 24(11):1197-207. PubMed ID: 400396
    [No Abstract]   [Full Text] [Related]  

  • 52. Clinical effects of intravenous nifedipine on renal function.
    Yokoyama S; Kaburagi T
    J Cardiovasc Pharmacol; 1983; 5(1):67-71. PubMed ID: 6186862
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Factors involved in the antihypertensive action of calcium antagonists.
    Garthoff B; Kazda S; Knorr A; Thomas G
    Hypertension; 1983; 5(4 Pt 2):II34-8. PubMed ID: 6345375
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Nitrendipine, a new calcium antagonist, as basis therapy in essential hypertension].
    Groth H; Stimpel M; Edmonds D; Mosca R; Vetter W
    Schweiz Rundsch Med Prax; 1985 May; 74(19):503-6. PubMed ID: 3160097
    [No Abstract]   [Full Text] [Related]  

  • 55. Pharmacological basis for use of calcium antagonists in hypertension.
    Scriabine A; Kazda S
    Magnesium; 1989; 8(5-6):253-65. PubMed ID: 2693846
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Renal hemodynamic and tubular transport effects of nitrendipine.
    Wallia R; Greenberg A; Puschett JB
    J Lab Clin Med; 1985 Apr; 105(4):498-503. PubMed ID: 3156937
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Antihypertensive and humoral effects of verapamil and nifedipine in essential hypertension.
    Muiesan G; Agabiti-Rosei E; Castellano M; Alicandri CL; Corea L; Fariello R; Beschi M; Romanelli G
    J Cardiovasc Pharmacol; 1982; 4 Suppl 3():S325-9. PubMed ID: 6184562
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Haemodynamic (systemic and renal) and humoral interactions between nicardipine and domperidone in hypertensives.
    Lucarini AR; Salvetti A
    J Hypertens Suppl; 1987 Dec; 5(5):S571-4. PubMed ID: 3327930
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Nitrendipine reverses vasoconstriction and renal hemodynamic changes in experimental hypertension.
    Sterzel RB; Huelsemann JL; McKenzie DE; Wilcox CS
    J Cardiovasc Pharmacol; 1984; 6 Suppl 7():S1024-7. PubMed ID: 6085360
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Catecholamines, renin-angiotensin-aldosterone, and cardiovascular response during exercise following acute and long-term calcium antagonism with felodipine in essential hypertension.
    Katzman PL; Hulthén UL; Hökfelt B
    J Cardiovasc Pharmacol; 1987 Oct; 10(4):439-44. PubMed ID: 2444797
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.